Immunome Inc. 4

Immunome Inc. CFO Max Rosett received 47,250 RSUs and 94,500 stock options (exercise price $22.01) as part of an equity compensation grant on July 23, 2026.

On July 23, 2026, Immunome Inc. Chief Financial Officer Max Rosett received an equity compensation package consisting of 47,250 restricted stock units (RSUs) and 94,500 employee stock options with an exercise price of $22.01 per share. The RSUs, which represent the contingent right to receive one share of common stock per unit, will vest in four equal annual installments on each anniversary of the grant date, subject to continued service. The stock options will vest 25% on July 23, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, and are exercisable until July 22, 2036. Following these awards, Rosett beneficially owns 101,287 shares of Immunome common stock, reflecting a material but routine executive compensation grant with no open‑market purchases or sales reported.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001994071-26-000006

Alert Tier

6